123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.
about
PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challengesMolecular-genetic imaging of cancer.Endosomal pH-Responsive Polymer-Based Dual-Ligand-Modified Micellar Nanoparticles for Tumor Targeted Delivery and Facilitated Intracellular Release of Paclitaxel.Combined SPECT and Multidetector CT for Prostate Cancer Evaluations.Development of targeted near-infrared imaging agents for prostate cancerRadionuclide Therapy of Bone Metastases.Functional imaging for prostate cancer: therapeutic implications.Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.A multivalent approach of imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigenPET imaging in prostate cancer: focus on prostate-specific membrane antigenNext revolution in molecular theranostics: personalized medicine for urologic cancers.A review of the ligands and related targeting strategies for active targeting of paclitaxel to tumours.Small Molecules for Active Targeting in Cancer.Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.Synthesis and Evaluation of Gd(III) -Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane AntigenPSMA-mediated endosome escape-accelerating polymeric micelles for targeted therapy of prostate cancer and the real time tracing of their intracellular trafficking.Preparation and evaluation of carborane-derived inhibitors of prostate specific membrane antigen (PSMA).Metal-Based PSMA Radioligands.A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA).Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara® for prostate cancer therapy.Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.Triazole Appending Agent (TAAG): A New Synthon for Preparing Iodine-Based Molecular Imaging and Radiotherapy Agents.⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer.PSMA as a target for radiolabelled small molecules.Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer.68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.PSMA-targeted dendrimers: a patent evaluation (WO2012078534).Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer.Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy.Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges.Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.[(68)Ga-PSMA as a new tracer for evaluation of prostate cancer: comparison between PET-CT and PET-MRI in biochemical recurrence].PSMA Theranostics: Current Status and Future Directions.BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study)
P2860
Q28067404-9709B088-DFEC-40AB-A164-7633525274F0Q35116121-DFD030C4-245E-4830-9F8E-E9EF23BA25B7Q35560114-2A76382A-474F-4666-ADF2-F5CF31AF36C2Q35679253-EF9B8D3E-8D6D-48E5-9CB2-6A7E0D304348Q35754837-F401E24A-7FCB-4832-8288-E60638B7EB26Q36036136-2360311F-857F-4BA0-84F4-6CE8284808BEQ36128629-E1EB01F3-1EC6-49A9-AB7E-9F9A00EA8CF5Q37091554-CF43E7A6-3A67-41B8-9572-CF2A21056DD8Q37134019-4543C687-6BBC-4A59-BC6E-5B2DAD786988Q38099369-AC158979-06B1-4EC1-8957-0EDF6246FD21Q38559336-F22F84D4-458E-41CE-88F2-280B94F8AC99Q38733989-0BB5CEE5-8D36-44F6-823E-C6E187BE420BQ38780383-7BCDF7F7-C1D5-4E47-9E0B-9FEF2E74612FQ38820744-4C01EF23-91C2-43E9-8E41-CEF78939D448Q38849192-FE8A101A-CB7D-43A4-A32E-B439D2F427F7Q38938291-EC27C124-264C-491B-B441-EA91DDAF3A3AQ39028837-1A8CB780-8A88-4324-842C-17E9AE9DBF11Q39198527-9A2893DF-2223-4F53-A1F8-FDED0934C0D0Q39420655-65938678-FBFA-4966-A60D-93C486B99E85Q39456135-B83A1AA7-CB10-4A9B-8417-5CBEA90E8DB8Q39697612-167ACA61-80E8-45AC-AE20-0610E259DF9DQ39735976-01EF96D1-E21B-4B5E-B531-660EDC6E6127Q39828822-7070604A-BF0E-468D-AF02-2BB12954D6C6Q41600550-53DA0BBD-0FC2-419B-BDB1-0AAE2A49E3CEQ43177005-5CBD924D-0E54-4BA0-8976-3C206D58EA18Q43478484-7CAEB000-10D7-4B78-9B22-B5AA95C2B50CQ46225464-F03BCDC1-6BB7-40AA-BF75-29E2364500EBQ46795860-DB8DACD3-D76E-4949-BCAC-19F93F451094Q47097395-9BF66EE5-9835-4FE4-8A00-5315DA02C847Q47399411-6DAA32C8-3309-47AC-9F91-A1C496183BFAQ48116656-2EAB63E0-74CC-4E4E-900D-002461490672Q48905216-9E396E31-C3B5-4F8A-85D6-74BFA0A559E7Q53031006-A1953927-C7F7-4E39-8E40-E14B88332836Q55023828-0C0EC47B-F253-4741-ADE0-56209DC5DF25Q57815798-FE79EE60-F847-4068-9E1F-5561FDC0B227
P2860
123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
123I-MIP-1072, a small-molecul ...... or response to taxane therapy.
@en
123I-MIP-1072, a small-molecul ...... or response to taxane therapy.
@nl
type
label
123I-MIP-1072, a small-molecul ...... or response to taxane therapy.
@en
123I-MIP-1072, a small-molecul ...... or response to taxane therapy.
@nl
prefLabel
123I-MIP-1072, a small-molecul ...... or response to taxane therapy.
@en
123I-MIP-1072, a small-molecul ...... or response to taxane therapy.
@nl
P2093
P1476
123I-MIP-1072, a small-molecul ...... or response to taxane therapy.
@en
P2093
Ashley M Kern
John C Marquis
John L Joyal
John W Babich
Kevin P Maresca
Shawn M Hillier
William C Eckelman
P304
P356
10.2967/JNUMED.110.086751
P407
P577
2011-06-16T00:00:00Z